RxDoctor Payments Data

Feonie Eleuterio

Family · Lithonia, GANPI 1659808335

Payments from drug & device makers

$1,610in general payments, 2019–2025

Across 68 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$423
  • Johnson & Johnson$386
  • Viiv Healthcare Company$274
  • Novo Nordisk$195
  • GSK$120
  • Merck$113
  • plus $99 from 3 others

What the payments were for

  • Food & beverage$1,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,610 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$6,751
Medicare patients
58
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate37$56,027
BiktarvyBictegrav/Emtricit/Tenofov Ala14$54,619
OzempicSemaglutide27$51,758
TrulicityDulaglutide33$48,343
XareltoRivaroxaban27$27,624
FarxigaDapagliflozin Propanediol13$21,991
EliquisApixaban18$20,618
JardianceEmpagliflozin22$18,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,859
SymbicortBudesonide/Formoterol Fumarate22$11,312
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$5,155
Doxepin Hcl13$4,000
Albuterol Sulfate HfaAlbuterol Sulfate144$3,944
Duloxetine Hcl30$2,396
Atorvastatin Calcium344$2,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$113$56,02737 claims
GileadBiktarvy$423$54,61914 claims
Novo NordiskOzempic$195$51,75827 claims
Johnson & JohnsonXarelto$386$27,62427 claims
GSKTrelegy Ellipta$120$15,85917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Lithonia

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →